This is a ready-to-use hold-time study protocol for a biologics in-process intermediate (a bag, tank, or vessel hold between manufacturing steps). Replace every <<FILL: ...>> placeholder with your own specifics, set your document numbers and dates, and route it through your normal document control, review, and approval before execution. A worked filled specimen follows. Verify each cited regulation against the current source before you rely on it.
Approval page (execute only after all signatures)
| Field | Entry |
|---|---|
| Protocol title | Hold-Time Study for <<FILL: INTERMEDIATE NAME, e.g. Protein A eluate>> |
| Protocol number | <<FILL: PROT-ID, e.g. VAL-HT-009>> |
| Version | <<FILL: version>> |
| Effective date | <<FILL: date>> |
| Supersedes | <<FILL: prior version or "New">> |
| Hold point in process | <<FILL: e.g. between Protein A elution and AEX load>> |
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (Process development / Validation) | <<FILL>> | ||
| QC micro | <<FILL>> | ||
| QC analytical | <<FILL>> | ||
| Quality Assurance (approver) | <<FILL>> |
1. Objective
To establish the maximum validated hold time for <<FILL: INTERMEDIATE NAME>>, held at <<FILL: temperature condition>> in <<FILL: container type>>, beyond which product quality or microbial control can no longer be assured.
2. Scope
In scope: the hold point defined above, at the container, fill volume, and temperature condition used in manufacturing. Out of scope: other hold points in the process, each of which requires its own protocol or is bracketed here with documented justification: <<FILL: bracketing rationale or "not applicable">>.
3. Worst-case conditions to challenge
| Parameter | Manufacturing range | Worst case challenged | Rationale |
|---|---|---|---|
| Temperature | <<FILL: e.g. 2-8 C>> | <<FILL: high end, faster growth/degradation>> | <<FILL>> |
| Container / closure | <<FILL>> | <<FILL: actual production container, not a surrogate>> | <<FILL>> |
| Fill volume / surface-area-to-volume | <<FILL>> | <<FILL: worst-case ratio for adsorption/growth>> | <<FILL>> |
| Protein concentration | <<FILL>> | <<FILL: most/least concentrated, whichever is worse>> | <<FILL>> |
4. Responsibilities
| Role | Responsibility |
|---|---|
| Process development / Validation lead | Designs the study, defines worst case, interprets results into the validated hold window |
| QC micro | Runs bioburden and endotoxin testing at each time point |
| QC analytical | Runs product-quality assays (aggregate, charge variant, purity, appearance) |
| Manufacturing | Generates or provides representative hold material; later enforces the validated window in the batch record |
| QA | Approves the validated limit and confirms the batch record hard-stops holds beyond it |
5. Time points
| Time point | Purpose |
|---|---|
| 0 hours | Baseline |
<<FILL: intended maximum hold, e.g. 48 h>> | Target hold, must pass |
<<FILL: margin, e.g. 72 h>> | Margin beyond target, confirms the limit is not on a cliff edge |
6. Test cases
| TC ID | Time point | Attribute | Method | Limit | Result | Pass/Fail |
|---|---|---|---|---|---|---|
| TC-01 | 0 h | Aggregate (% HMW) | <<FILL: SEC>> | <<FILL>> | <<FILL>> | <<FILL>> |
| TC-02 | Target hold | Aggregate (% HMW) | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| TC-03 | Target hold | Bioburden | <<FILL: plate count>> | <<FILL>> | <<FILL>> | <<FILL>> |
| TC-04 | Target hold | Endotoxin | <<FILL: LAL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| TC-05 | Margin | All above | <<FILL>> | <<FILL>> |
7. Cumulative hold-time accounting
Where this hold point stacks with others upstream of a shared boundary (most often final filtration or fill), state the cumulative limit here so per-step limits cannot be individually satisfied while the total exceeds what is safe: <<FILL: e.g. "combined with the post-AEX hold, total time before final filtration shall not exceed 96 h">>.
8. Acceptance criteria
- All monitored attributes remain within limit at the target hold time, with no adverse trend.
- The margin time point also passes, or if it does not, the target hold is set below whichever time point last passed with margin.
- Bioburden and endotoxin remain within limit at every tested time point.
- Where applicable, the cumulative hold-time limit is respected.
9. Deviation handling
Any deviation (a missed time point, an out-of-trend result, a container or temperature excursion during the study) is raised through <<FILL: SOP-ID for deviations>> and its impact on the validated hold claim is assessed before the study is considered complete.
10. Summary and conclusion (completed at report stage)
Reference the hold-time study report <<FILL: report number>>, which states the validated maximum hold time, the temperature condition, the container, all deviations, and the conclusion. The validated hold window is written into the batch record as a hard limit per <<FILL: batch record reference>>.
11. References
FDA Guidance for Industry, Process Validation: General Principles and Practices (January 2011). 21 CFR 211.111 (time limitations on production). EudraLex Volume 4, Annex 2 and Annex 15.
Confirm the current version and clause numbers of each reference before issue.
12. Attachments
Representative material generation record; container/closure specification; analytical method references.
13. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
Filled specimen (excerpt)
Illustrative Protein A eluate, held 2-8 C in a single-use bag.
| Hold time (h) | Aggregate (% HMW) | Bioburden (CFU/10 mL) | Endotoxin (EU/mL) | Result |
|---|---|---|---|---|
| 0 | 1.0 | less than 1 | less than 0.05 | Pass |
| 48 (target) | 1.1 | less than 1 | less than 0.05 | Pass |
| 72 (margin) | 1.2 | less than 1 | 0.06 | Pass |
| Limit | less than or equal to 2.0 | less than or equal to 10 | less than or equal to 0.25 |
Conclusion (illustrative): validated hold is 48 hours at 2-8 C in the qualified single-use bag. The 72-hour margin point still passes, so the limit is not at a cliff edge.
Common inspection findings this protocol prevents
- Hold limits routinely exceeded in production with no deviation raised.
- No microbial endpoint tested, only product quality, missing the bioburden/endotoxin growth risk.
- Container in the study (e.g., glass bottle) not representative of the actual production container (e.g., single-use bag).
- Worst case not actually challenged (low end of temperature range studied when the high end is the real risk).
- Cumulative hold time across multiple stacked holds never assessed as a total.
How to adapt this protocol
- Set your protocol number, intermediate name, and hold point in the approval page.
- Confirm the worst-case temperature, container, and concentration reflect the true risk direction, not just convenience.
- Add a cumulative hold-time statement if this hold point stacks with others before a shared boundary.
- Confirm every regulation in section 11 against the current published version before issue.